Journal ArticleDOI
The Myeloproliferative Neoplasm Symptom Assessment Form (MPN-SAF): international prospective validation and reliability trial in 402 patients
Robyn M. Scherber,Amylou C. Dueck,Peter Johansson,Tiziano Barbui,Giovanni Barosi,Alessandro M. Vannucchi,Francesco Passamonti,Bjorn Andreasson,Maria L Ferarri,Alessandro Rambaldi,Jan Samuelsson,Gunnar Birgegård,Ayalew Tefferi,Claire N. Harrison,Deepti Radia,Ruben A. Mesa +15 more
TLDR
The MPN-SAF is a comprehensive and reliable instrument that is available in multiple languages to evaluate symptoms associated with all types of MPNs in clinical trials globally.About:
This article is published in Blood.The article was published on 2011-07-14. It has received 282 citations till now. The article focuses on the topics: Myeloproliferative neoplasm & Essential thrombocythemia.read more
Citations
More filters
Journal ArticleDOI
Myeloproliferative Neoplasm (MPN) Symptom Assessment Form Total Symptom Score: Prospective International Assessment of an Abbreviated Symptom Burden Scoring System Among Patients With MPNs
Robyn M. Emanuel,Amylou C. Dueck,Holly L. Geyer,Jean-Jacques Kiladjian,Stefanie Slot,Sonja Zweegman,Peter A. W. te Boekhorst,Suzan Commandeur,Harry C. Schouten,Federico Sackmann,Ana Kerguelen Fuentes,Dolores Hernández-Maraver,Heike L. Pahl,Martin Griesshammer,Frank Stegelmann,Konstanze Doehner,Thomas Lehmann,Karin Bonatz,Andreas Reiter,Françoise Boyer,Gabriel Etienne,Jean Christophe Ianotto,Dana Ranta,Lydia Roy,Jean-Yves Cahn,Claire N. Harrison,Deepti Radia,Pablo J. Muxi,Norman Maldonado,Carlos Besses,Francisco Cervantes,Peter L. Johansson,Tiziano Barbui,Giovanni Barosi,Alessandro M. Vannucchi,Francesco Passamonti,Bjorn Andreasson,Maria L Ferarri,Alessandro Rambaldi,Jan Samuelsson,Gunnar Birgegård,Ayalew Tefferi,Ruben A. Mesa +42 more
TL;DR: The MPN-SAF TSS is a concise, valid, and accurate assessment of MPN symptom burden with demonstrated clinical utility in the largest prospective MPN symptoms study to date.
Journal ArticleDOI
Safety and efficacy of CYT387, a JAK1 and JAK2 inhibitor, in myelofibrosis
Animesh Pardanani,Rebecca R. Laborde,Terra L. Lasho,Christy Finke,Kebede H. Begna,Aref Al-Kali,William J. Hogan,Mark R. Litzow,Alexey A. Leontovich,M Kowalski,A Tefferi +10 more
TL;DR: CYT387 is well tolerated and produces significant anemia, spleen and symptom responses in MF patients, and Plasma cytokine and gene expression studies suggested a broad anticytokine drug effect.
Journal ArticleDOI
Epidemiology of myelofibrosis, essential thrombocythemia, and polycythemia vera in the European Union.
TL;DR: There is a wide variation in both prevalence and incidence estimates observed across European data sources, and estimates of the population aimed to receive novel treatments for these neoplasms are better understood to assist public health planning and provide valuable information about the burden of illness.
Journal ArticleDOI
Revised response criteria for polycythemia vera and essential thrombocythemia: an ELN and IWG-MRT consensus project
Giovanni Barosi,Ruben A. Mesa,Guido Finazzi,Claire N. Harrison,Jean-Jacques Kiladjian,Eva Lengfelder,Mary Frances McMullin,Francesco Passamonti,Alessandro M. Vannucchi,Carlos Besses,Heinz Gisslinger,Jan Samuelsson,Srdan Verstovsek,Ronald Hoffman,Animesh Pardanani,Francisco Cervantes,Ayalew Tefferi,Tiziano Barbui +17 more
TL;DR: Revised recommendations for assessing response in ET and PV are presented by a working group established by ELN and International Working Group-Myeloproliferative Neoplasms Research and Treatment that include new definitions of complete and partial remission that include a standardized symptom assessment form.
Journal ArticleDOI
Epidemiology of myeloproliferative neoplasms in the United States.
TL;DR: The incidence of MF and prevalence of MF, ET and PV in the United States between 2008 and 2010 based on data from two large health plans and additional research is needed to substantiate these findings.
References
More filters
Journal ArticleDOI
The European Organization for Research and Treatment of Cancer QLQ-C30: A Quality-of-Life Instrument for Use in International Clinical Trials in Oncology
Neil K. Aaronson,Sam H Ahmedzai,Bengt Bergman,Monika Bullinger,Ann Cull,Nicole Duez,Antonio Filiberti,Henning Flechtner,Stewart B. Fleishman,Johanna C. J. M. de Haes,Stein Kaasa,M. Klee,David Osoba,Darius Razavi,Peter B. Rofe,Simon Schraub,Kommer C. A. Sneeuw,Marianne Sullivan,Fumikazu Takeda +18 more
TL;DR: The reliability and validity of the EORTC QLQ-C30 questionnaire were highly consistent across the three language-cultural groups studied: patients from English-speaking countries, Northern Europe, and Southern Europe.
Journal ArticleDOI
Principles of Good Practice for the Translation and Cultural Adaptation Process for Patient-Reported Outcomes (PRO) Measures: report of the ISPOR Task Force for Translation and Cultural Adaptation.
D Wild,Alyson Grove,Mona L. Martin,Sonya Eremenco,Sandra McElroy,A. Verjee-Lorenz,Pennifer Erikson +6 more
TL;DR: A consensus emerged on a broad approach, along with a detailed critique of the strengths and weaknesses of the differing methodologies in this review of translation and cultural adaptation of patient-reported outcome measures.
Journal ArticleDOI
The rapid assessment of fatigue severity in cancer patients: use of the Brief Fatigue Inventory.
Tito R. Mendoza,X. Shelley Wang,Charles S. Cleeland,Marilyn Morrissey,Beth A. Johnson,Judy K. Wendt,Stephen L. Huber +6 more
TL;DR: The Brief Fatigue Inventory was developed for the rapid assessment of fatigue severity for use in both clinical screening and clinical trials.
Journal ArticleDOI
Assessing symptom distress in cancer patients: The M. D. Anderson Symptom Inventory
Charles S. Cleeland,Tito R. Mendoza,Xin Shelley Wang,Chyi Chou,Margaret T. Harle,Marilyn Morrissey,Martha C. Engstrom +6 more
TL;DR: The purpose of this project was to develop the M. D. Anderson Symptom Inventory (MDASI), a brief measure of the severity and impact of cancer‐related symptoms.
Journal ArticleDOI
New prognostic scoring system for primary myelofibrosis based on a study of the International Working Group for Myelofibrosis Research and Treatment.
Francisco Cervantes,Brigitte Dupriez,Arturo Pereira,Francesco Passamonti,John T. Reilly,Enrica Morra,Alessandro M. Vannucchi,Ruben A. Mesa,Jean Loup Demory,Giovanni Barosi,Elisa Rumi,Ayalew Tefferi +11 more
TL;DR: In 409 patients with assessable metaphases, cytogenetic abnormalities were associated with shorter survival, but their independent contribution to prognosis was restricted to patients in the intermediate-risk groups.
Related Papers (5)
A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis
Srdan Verstovsek,Ruben A. Mesa,Jason Gotlib,Richard S. Levy,Vikas Gupta,John F. DiPersio,John Catalano,Michael W. Deininger,Michael W. Deininger,Carole B. Miller,Richard T. Silver,Moshe Talpaz,Elliott F. Winton,Jimmie H. Harvey,Murat O. Arcasoy,Elizabeth O. Hexner,Roger M. Lyons,Ronald Paquette,Azra Raza,Kris Vaddi,Susan Erickson-Viitanen,Iphigenia L. Koumenis,William Sun,Victor Sandor,Hagop M. Kantarjian +24 more
JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis.
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis.
Ross L. Levine,Ross L. Levine,Martha Wadleigh,Jan Cools,Benjamin L. Ebert,Benjamin L. Ebert,Gerlinde Wernig,Brian J. P. Huntly,Titus J. Boggon,Iwona Wlodarska,Jennifer J. Clark,Sandra A. Moore,Jennifer Adelsperger,Sumin Koo,Jeffrey C. Lee,Stacey Gabriel,Thomas Mercher,Alan D. D'Andrea,Stefan Fröhling,Konstanze Döhner,Peter Marynen,Peter Vandenberghe,Ruben A. Mesa,Ayalew Tefferi,James D. Griffin,Michael J. Eck,William R. Sellers,William R. Sellers,Matthew Meyerson,Matthew Meyerson,Todd R. Golub,Todd R. Golub,Todd R. Golub,Stephanie J. Lee,D. Gary Gilliland,D. Gary Gilliland,D. Gary Gilliland +36 more